Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BOSTON, June 02, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and...
-
– Six abstracts presented highlighting data on BylvayTM (odevixibat) and effects on pruritus, serum bile acids, growth and sleep parameters – Pre-clinical study of systemic ASBT/NTCP inhibitors,...
-
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation in the H.C. Wainwright...
-
Positive Bylvay™ (odevixibat) global commercial launch in U.S., Germany and United Kingdom with Q1 2022 product revenue, net $4.7 million Phase 3 ASSERT study in Alagille syndrome fully enrolled,...
-
BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a...
-
– Phase 3 ASSERT study on track to report topline data by the end of year – Albireo launches Expanded Access Program (EAP) for Alagille syndrome patients BOSTON, March 29, 2022 (GLOBE NEWSWIRE) --...
-
Bylvay™ (odevixibat) launched in the U.S. and Europe, 2021 product revenue, net $7 millionNICE endorses clinical and economic benefits of BylvayPhase 3 study in Alagille syndrome on track for readout...
-
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a...
-
– Decision provides access to the first drug treatment approved in PFIC for patients in England, Wales and Northern Ireland – Positive NICE review completed in less than six months post MHRA approval...
-
PFIC caregivers reported high impact on mental and physical health, productivity, career prospects, sleep, relationships and financesStudy suggests PFIC caregivers’ quality of life may be comparable...